Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
MDXH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $3.50
Previous CloseN/A
Volume27.23K
Average Volume (3M)89.48K
Market Cap
$69.79M
Enterprise Value$129.07M
Total Cash (Recent Filing)$3.52M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-1376.98
Next Earnings
May 14, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding49,497,334
10 Day Avg. Volume55,865
30 Day Avg. Volume89,482
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.25
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.34
Enterprise Value/Ebitda-6.64
Forecast
1Y Price Target
$6.50Price Target Upside342.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
MDxHealth News
PremiumCompany Announcements
Mdxhealth S.A. Reports Strong Revenue Growth in Earnings Call
PremiumCompany Announcements
Mdxhealth Reports Strong 2024 Financial Performance with 28% Revenue Growth
---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company is fully funded with a completed equity raise and access to its OrbiMed debt facility, allowing it to execute without reliance on choppy capital markets.
Growth DriversThe Company has four well-established tests being promoted, with germline testing in early limited launch, indicating growth drivers are in place for longer-term growth aspirations.
Product PortfolioTissue-based tests, which represent 80% of the Company’s revenues, are key products in the portfolio and have strong revenue generation potential.
Revenue GrowthManagement is confident in its ability to meet or exceed revenue guidance for 2025 and remains on track to flip to AEBITDA positivity.
Bears Say
Market PerformanceShares are down 48% year-to-date, driven down by financing overhang, limited market liquidity, and a somewhat negative sentiment toward the broader diagnostics space.
Valuation ConcernsShares remain depressed, representing an entry point for investors seeking growth with near-term bottom line improvement.
---
Ownership Overview
―
Insiders
0.08%
Mutual Funds
34.51% Other Institutional Investors
65.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $1.35 and its highest was $3.50 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $69.79M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is May 14, 2025 which is in 32 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Feb 26, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.192 by $0.052.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.13.
How many shares outstanding does MDxHealth have?
MDxHealth has 49,497,334 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.192. Following the earnings report the stock price went up 1.639%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
---
MDxHealth Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (342.18% Upside)
$6.50 (342.18% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.75%
12-Months-Change
Fundamentals
Return on Equity
-345.31%
Trailing 12-Months
Asset Growth
21.84%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
---
MDXH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and improved financial performance, despite a decline in gross margins and increased operating expenses. The company expressed confidence in achieving its revenue and adjusted EBITDA goals for 2025, driven by increased test volumes and strategic execution.Read More>---
MDXH Stock 12 Month Forecast
Average Price Target
$6.50
▲(342.18% Upside)
Technical Analysis
Best Analysts Covering MDXH
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-24.26%
reiterated a buy rating 8 days ago
Copying Thomas Flaten's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -24.26% per trade.
---